Skip to main content
Premium Trial:

Request an Annual Quote

Charles Ma, George Jokhadze, Thomas Higgins, Christohper Yoo, Kenneth Bate, Mark Levin, Ginger Graham, Vaughn Kailian, Edward Miller, Amit Kumar, and William Haseltine

Premium

Charles Ma has become chief scientist of Phalanx Biotech Group, and George Jokhadze director of operations of PhalanxBio, the group’s US subsidiary, the Taiwan-based microarray company said earlier this month. Jokhadze was previously a senior research scientist and group leader at BD Clontech, where he co-developed microarrays. He holds a PhD in molecular biology from the Academy of Sciences in Russia. Ma has been an associate research scientist at Columbia University since 1995. He holds a PhD in molecular biology from the University of California, Los Angeles.


Thomas Higgins has become CFO and executive vice president of Caliper Life Sciences, the company said last week. His appointment will become effective in early January. Higgins currently is executive vice president of operations and CFO of VI Technologies. He holds a BBA from Boston University.


Christohper Yoo will become director of marketing of the molecular biology division of Applied Biosystems starting in January. He joins ABI from IBM’s Information Based Medicine unit, where he was head of strategy. Yoo holds a PhD in molecular and cell biology from Yale University School of Medicine and a BA from the University of Pennsylvania.


Kenneth Bate will leave Millennium Pharmaceuticals, where he is head of commercial operations and an executive vice president, in January, the company said on Monday. His responsibilities will be taken over by CEO Mark Levin. Millennium is currently looking for a successor. In addition, three board members, Ginger Graham, CEO of Amylin Pharmaceuticals; Vaughn Kailian, managing partner of Deerhaven Partners; and Edward Miller, CEO and dean of Johns Hopkins University School of Medicine; will step down in January.


Amit Kumar, CEO and president of CombiMatrix, has been appointed to the board of the NanoBusiness Alliance, an industry association, CombiMatrix’s parent company Acacia Research said on Monday.


William Haseltine has joined the board of directors of the Institute for OneWorld Health, the non-profit company said last week. He was the CEO and chairman of Human Genome Sciences until this fall. Haseltine holds a PhD in biophysics from Harvard University and an undergraduate degree in physical chemistry from the University of California at Berkeley.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.